Sat, Jul 26, 2014, 10:29 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

ImmunoGen, Inc. Message Board

  • intrinsic5000 intrinsic5000 Jan 31, 2013 6:19 PM Flag

    Just to be clear

    T-DM1 is only approved for patients that have failed perception--right? So the "approvable" population is small, but we should be picking up off-label use. Obviously Roche doesn't want to cannabilize Herceptin sales. Wonder if the insurance companies won't be willing to pay for T-DM1, given the higher cost relative to Herceptin. If so, then how many "rich" people will be on this!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Full year 2012 sales for Herceptin reported by Roche $5,889 CHF. In US dollars that is ~$6.5 billion. By 2015 Roche will likely have completed their trial and received approval for TDM1 for 1st line MBC. I see from the Roche materials that there is also data expected from a gastric clinical trial expected in 2015, and also early BC (not MBC, but early BC) in 2016.

      Also from the Roche materials the Herceptin market grew 11% in 2012. So for easy math and a good conversation to have with friends over beers after work, assume that TDM1 will have a minimum of a 20% price increase over Herceptin, and over the next two years grows at 11% and the majority of the Herceptin franchise has been transitioned over to TDM1. So by 2015 you might see sales of TDM1 approaching over $9 billion annually. Now that is a bullish outlook, even from me who has followed this story since early 2009.

      Chinese Hamsters

      • 2 Replies to chinesehamsters
      • Thanks, as always CH. 5% of 9BB is 450MM. To keep the math simple, assume IMGN has 100MM shares outstanding that's $4.50 per share. At a 20 multiple we get $90/share. Hopefully, by then another compound, or multiple compounds are well advanced and IMGN is not valued just based on projected and underestimated T-DM1 revs, as is the current situation. I just got excited! Holding a LT position and trading some based on the technicals works for IMGN IMO.

      • The possible revenue numbers and royalties are not yet recognized by anybody that works in the investment community- not that I can find. At the same time you have a boatload of short-sellers who make a habit of shorting low or no sales revenue biotech stocks in late- stage trials expecting denials or delays- historically they are right way more than wrong. I think we may have a perfect wave building here.......

    • Being able to charge for a higher premium for T-DM1 and the fact that herceptin is going off patent, the goal of Roche is to replace Herceptin with T-DM1. I would not be surprised if T-DM1 will be used as a first line agent in many cases. T-DM1 sales will exceed most analyst projections.

    • Are you referring to the real rich or the Obama fantasyland rich?

    • Roche intends to transition every HER 2+ cancer patient onto TDM1 over time. As the label expansions come, thus TDM1 sales will increase. Herceptin goes off patent in a few years and there will be biosims available to try and take a piece of that Herceptin franchise. By the time that happens TDM1 will be probably close to or approved as front line therapy for breast cancer and perhaps other HER 2+ cancers.

      I wouldn't really say that Roche is cannibalizing Herceptin since TDM1 is Herceptin + DM1, rather they are building on an existing foundation and have a better more efficacious drug to offer patients, thus obviating a very large percentage of the existing Herceptin market.

      Chinese Hamsters

    • I meant WILL BE APPROVED

    • failed HERCEPTIN not perception LOL

10.63-0.26(-2.39%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.